Wednesday, 17 January 2024
| Wednesday, 17 January 2024 | |
|---|---|
| 8:00 – 17:00 | Poster Hall Setup |
| 9:00 – 20:30 | Registration Opens |
| 18:00 – 19:30 | Convention Hall I - A/B Welcome and Opening Remarks Lifetime Achievement Awards Presentation Ceremony |
| 19:30 – 21:30 | Convention Hall I - C/D Welcome Reception Poster and Exhibit Hall Open |
| Thursday, 18 January 2024 | |
|---|---|
| 7:00 – 18:30 | Registration/Information |
| 7:30 – 8:30 | Breakfast Poster and Exhibit Hall Open |
| 8:30 – 12:00 | Convention Hall I - A/B Plenary Session Chair: David Simpson, MD (USA) |
| 8:30 – 8:45 | Opening remarks and introduction of keynote speaker David Simpson, MD (USA) |
| 8:45 – 9:30 | Molecular mechanisms of presynaptic nerve cell signaling in health and disease Keynote Speaker: Nils Brose, PhD (Germany) |
| 9:30 – 10:00 | Muscle physiology Preeti Raghavan, MD (USA) |
| 10:00 – 10:30 | Insights from dystonia: How might muscles respond to neurological diseases? Rob Brownstone, FMedSci (UK) |
| 10:30 – 11:00 | Break Poster and Exhibit Hall Open |
| 11:00 – 11:30 | Long-term effects at the neuromuscular junction—motor function recovery Juan P. Henríquez, PhD (Chile) |
| 11:30 – 12:00 | An evidence-based medicine review of botulinum neurotoxin (BoNT) injections guided by ultrasound and EMG Barbara Karp, MD (USA) |
| 12:00 – 13:30 | Lunch |
| 12:00 – 14:00 | Break Poster and Exhibit Hall Open |
| Time | Basic Science Track Room I |
Time | Clinical Track 1A Room V |
Time | Clinical Track 2A Room III |
Time | Clinical Track 3A Room IV |
Time | Clinical Track 4A Convention Hall I A/B |
Time | Clinical Track 5A Estrel A/B |
Time | Clinical Track 6A Estrel C |
Time | Clinical Track 7A Paris |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14:00 – 15:30 | Genetics and Evolution Chair: Sabine Pellett, PhD (USA) Co-Chair: Carolina Luquez, PhD (USA) |
14:00 – 15:30 | Focal Limb Dystonia, Tremor and Tics Chair: David Simpson, MD (USA) |
14:00 – 15:30 | Aesthetics and Dermatology I Chair: Michael Kane, MD (USA) |
14:00 – 15:30 | Adult Spasticity I Chair: Alberto Esquenazi, MD (USA) |
14:00 – 15:30 | Migraine and Headache Chair: Cristina Tassorelli, MD (Italy) |
14:00 – 15:30 | Injection Demonstration Workshop: Cervical Dystonia Moderator: Alberto Albanese, MD (Italy) |
14:00 – 15:30 | Oromandibular Dystonia/Spasmodic Dysphonia Chair: Andrew Blitzer, MD, DDS (USA) |
14:00 – 15:30 | Ultrasound Workshop: Lower Limb Chair: Katharine Alter, MD (USA) |
|||||||
| 14:00 – 14:20 | Ancient clostridium species and neurotoxins revealed by metagenomic analysis of human archaeological remains Andrew C. Doxey, PhD (Canada) |
14:00 – 14:25 | BoNT for tics Sarah Pirio-Richardson, MD, FAAN (USA) |
14:00 – 14:25 | Gender, ethnic, and age considerations for the use of neuromodulators in facial aesthetics Patricia Ogilvie, MD (Germany) |
14:00 – 14:25 | Modeling long-term outcomes for BoNT-A in patients with post-stroke spasticity Klemens Fheodoroff, MD (Austria) |
14:00 – 14:25 | Newer proposed mechanisms of action of BoNT-A in migraine Rami Burstein, PhD (USA) |
14:00 – 15:30 | Injectors: Urban Fietzek, MD (Germany) Walter Raffauf, MD (Germany) |
14:00 – 14:20 | Spasmodic dysphonia Andrew Blitzer, MD, DDS (USA) |
14:00 – 15:30 | Katharine Alter, MD (USA) Heakyung Kim, MD (USA) Serdar Koçer, MD (Switzerland) Steffen Berweck, MD (Germany) Sebastian Schroeder, MD (Germany) Michael Munin, MD (USA) Sophie Cho, MD (USA) Atul Patel, MD (USA) Panagiotis Kassavetis, MD, PhD (USA) Yeva Fernandez, MD (USA) |
|||||||
| 14:20 – 14:40 | Towards understanding the role of OrfX/P47 Maria Nowakowska, MSc (Finland) |
14:25 – 14:45 | Ten years of musician's dystonia: Individual responses to treatment Michele Vecchio, MD, PhD (Italy) |
14:25 – 14:50 | Ptosis: What can we do about this? Michael Kane, MD (USA) |
14:25 – 14:45 | Online monitoring of long-term spasticity management with BoNT-A Alexander Geurts, MD, PhD (Netherlands) |
14:25 – 14:50 | Migraine and headache update Cristina Tassorelli, MD (Italy) |
14:20 – 14:40 | Diagnosis, choices of muscles to be treated with BoNT, outcomes and expectations Andrew Blitzer, MD, DDS (USA) |
|||||||||||
| 14:40 – 15:00 | Evaluation of botulinum neurotoxin serotype F in a bivalent Bf strain isolated from an infant botulism case, 2018 Victoria Foltz, BSc (USA) |
14:45 – 15:10 | Essential tremor Sanjay Pandey, MD (India) |
14:50 – 15:15 | Hyperhidrosis update Marcus Naumann, MD (Germany) |
14:45 – 15:10 | Spasticity-related quality of life: Six dimensions instrument (SQoL-6D) in upper limb spasticity Jorge Jacinto, MD (Portugal) |
14:40 – 15:00 | Motor and phonic tics Andrew Blitzer, MD, DDS (USA) |
|||||||||||||
| 15:00 – 15:30 | Mimicking the multivalent binding of bacterial protein toxins to their cellular receptors in a native-like membrane environment Laura-Varenne Wilk, PhD (Germany) |
15:10 – 15:30 | IncobotulinumtoxinA in the treatment of musician’s focal hand dystonia: A placebo-controlled, crossover trial David Simpson, MD (USA) |
15:15 – 15:30 | Panel Discussion |
15:10 – 15:20 | Choice of shoulder muscles for the multi-pattern treatment of upper limb spasticity with botulinum neurotoxin injections Jörg Wissel, MD, FRCP (Germany) |
14:50 – 15:30 | Injection Demonstration Workshop: Migraine and Headache Moderator: Cristina Tassorelli, MD (Italy) Injector: Heike Israel-Willner, MD (Germany) |
15:00 – 15:20 | Tongue muscles Raymond Rosales, MD, PhD (Philippines) |
|||||||||||
| 15:20 – 15:30 | A practical booklet for ultrasound-guided botulinum toxin injections Stefano Carda, MD (Switzerland) |
15:20 – 15:30 | Panel Discussion |
|||||||||||||||||||
| 15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
|||||||
| Time | Basic Science Track Room I |
Time | Clinical Track 1B Room V |
Time | Clinical Track 3B Room IV |
Time | Clinical Track 4B Convention Hall I A/B |
Time | Clinical Track 5B Estrel A/B |
Time | Clinical Track 6B Estrel C |
Time | Clinical Track 7B Paris |
|||||||||
| 16:15 – 17:45 | Structural insights of BoNTs Chair: Min Dong, PhD (USA) Co-Chair: Andreas Rummel, PhD (Germany) |
16:15 – 17:45 | Pain Chair: Bahman Jabbari, MD (USA) |
16:15 – 17:45 | Pediatric Spasticity (and Other Conditions for BoNT Relative to the Pediatric Patient) Chair: Sebastian Schroeder, MD (Germany) |
16:15 – 17:45 | Injection Demonstration Workshop: Aesthetics and Dermatology Moderator: Steve Yoelin, MD (USA) Moderator: Patricia Ogilvie, MD (Germany) |
16:15 – 17:45 | Injection Demonstration Workshop: Oromandibular Dystonia/Hemifacial Spasm Moderator: Andrew Blitzer, MD, DDS (USA) |
16:15 – 17:45 | Cervical Dystonia - Advanced Injection Techniques Chair: Marie Vidailhet, MD (France) |
16:15 – 17:45 | Ultrasound Workshop: Upper Limb Chair: Katharine Alter, MD (USA) |
|||||||||
| 16:15 – 16:35 | Cryo-EM structures of the 300 kDa progenitor toxin complexes of BoNT/B, BoNT/X, BoNT/Wo and PMP1 Pål Stenmark, PhD (Sweden) |
16:15 – 16:45 | Trigeminal neuralgia Lars Bendtsen, MD, PhD, Dr.Med.Sci (Denmark) |
16:15 – 16:45 | Spasticity management with BoNT: Clinical trial update Mark Gormley, MD (USA) |
16:15 – 17:45 | Injectors: Tanja Fischer, MD (Germany) Eric Petzold, MD (Germany) Patricia Ogilvie, MD (Germany) |
16:15 – 17:45 | Injectors: Andrea Stenner, MD (Germany) Martina Müngersdorf, MD (Germany) |
16:15 – 16:35 | Functional anatomy and clinical patterns of cervical dystonia Sherry Downie, PhD (USA) |
16:15 – 17:45 | Katharine Alter, MD (USA) David Simpson, MD (USA) Serdar Koçer, MD (Switzerland) Steffen Berweck, MD (Germany) Michael Munin, MD (USA) Sophie Cho, MD (USA) Atul Patel, MD (USA) Yeva Fernandez, MD (USA) |
|||||||||
| 16:35 – 16:55 | Receptor-binding mechanism of botulinum neurotoxins Rongsheng Jin, PhD (USA) |
16:45 – 17:15 | Pelvic pain Barbara Karp, MD (USA) |
16:45 – 17:15 | Thinking outside of the box: Treating patients with severe disabilities and complex problems Cindy B. Ivanhoe, MD (USA) |
16:35 - 16:55 | Optimizing outcomes from BoNT for cervical dystonia: The importance of guidance Panagiotis Kassavetis, MD, PhD (USA) |
|||||||||||||||
| 16:55 – 17:15 | Lessons learnt from the structural aspects of botulinum neurotoxin research so far K. Ravi Acharya, PhD (UK) |
16:55 – 17:20 | Options for injecting BoNT in the longus colli and longus capitis muscles in the management of dystonic head flexion Anterior approach Lucy Hicklin, FRCS (UK) Antero-lateral approach Panagiotis Kassavetis, MD, PhD (USA) |
|||||||||||||||||||
| 17:15 – 17:35 | Excitation-contraction-coupling inhibitors potentiate the activity of botulinum neurotoxin type A at the neuromuscular junction Mickaël Machicoane, PhD (Switzerland) |
17:15 – 17:45 | BoNT for unusual pain conditions: Postherpetic neuralgia/occipital neuralgia, neuropathic pain/diabetic neuropathy Bahman Jabbari, MD (USA) |
17:15 – 17:45 | Sialorrhea Heakyung Kim, MD (USA) |
17:20 - 17:35 | Deep posterior muscles Alexandre Kreisler, MD, PhD (France) |
|||||||||||||||
| 17:35 – 17:45 | Structure-based design of a botulinum neurotoxin with triple receptor recognition Geoffrey Masuyer, PhD (Sweden) |
17:35 - 17:45 | Panel Discussion |
|||||||||||||||||||
| 18:00 – 19:00 | Room I INA Business Meeting |
18:00 - 19:00 | Room I INA Business Meeting |
18:00 - 19:00 | Room I INA Business Meeting |
18:00 - 19:00 | Room I INA Business Meeting |
18:00 - 19:00 | Room I INA Business Meeting |
18:00 - 19:00 | Room I INA Business Meeting |
18:00 - 19:00 | Room I INA Business Meeting |
| Friday, 19 January 2024 | |
|---|---|
| 7:00 – 18:30 | Registration/Information |
| 7:30 – 8:30 | Breakfast Poster and Exhibit Hall Open |
| 8:30 – 12:00 | Convention Hall I - A/B Plenary Session Chair: Giampietro Schiavo, PhD, FMedSci, FRSB (UK) |
| 8:30 – 8:45 | Welcome Back Giampietro Schiavo, PhD, FMedSci, FRSB (UK) |
| 8:45 – 9:30 | The somatosensory perception of pain and temperature Peter McNaughton, DPhil, PhD (UK) |
| 9:30 – 10:10 | Is there a role for botulinum toxin therapy in cancer patients? Bahman Jabbari, MD (USA) |
| 10:10 – 10:40 | Break Poster and Exhibit Hall Open |
| 10:40 – 11:20 | BoNT actions beyond neurons Sara Marinelli, PhD (Italy) |
| 11:20 – 12:00 | The use of BoNT in patients with tremor Mandar Jog, MD (Canada) |
| 12:00 – 13:30 | Lunch |
| 12:00 – 14:00 | Break Poster and Exhibit Hall Open |
| Time | Basic Science Track Room I |
Time | Clinical Track 1A Room III |
Time | Clinical Track 2A Estrel C |
Time | Clinical Track 3A Convention Hall I A/B |
Time | Clinical Track 4A Estrel A/B |
Time | Clinical Track 5A Room V |
Time | Clinical Track 6A Room IV |
Time | Clinical Track 7A Paris |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14:00 – 15:30 | Cell Biology of BoNTs Chair: Ornella Rossetto, PhD (Italy) Co-Chair: Giampietro Schiavo, PhD, FMedSci, FRSB (UK) |
14:00 – 15:30 | Aesthetics and Dermatology II Chair: Nowell Solish, MD (Canada) |
14:00 – 15:30 | Adult Spasticity II Chair: Anthony Ward, MBE, BSc, MD, FRCP (UK) |
14:00 – 15:30 | The Patient With Parkinson’s Disease (Multiple Conditions Treated With BoNT) Chair: Francisco Cardoso, MD (Brazil) |
14:00 – 15:30 | Injection Demonstration Workshop: Pediatric Spasticity Moderator: Steffen Berweck, MD (Germany) |
14:00 – 15:30 | Blepharospasm/Meige Syndrome Chair: Marie-Helene Marion, MD (UK) |
14:00 – 15:30 | Depression and Other Mental Disorders Chair: Marc Axel Wollmer, MD (Germany) |
14:00 – 15:30 | Ultrasound Workshop: Head & Neck Chair: Katharine Alter, MD (USA) |
|||||||
| 14:00 – 14:20 | Decoding sneaky botulinum neurotoxin type A neuronal break-in into synaptic vesicles using super-resolution microscopy Fred Meunier, PhD (Australia) |
14:00 – 14:25 | How botulinum toxin can restore a facial expression after facial palsy Daniel Labbé, MD (France) |
14:00 – 14:30 | Does a diagnostic nerve block predict the outcome of botulinum toxin treatment? Anthony Ward, MBE, BSc, MD, FRCP (UK) |
14:00 – 14:20 | Botulinum toxin in parkinsonian disorders Robert Chen, MD (Canada) |
14:00 – 15:30 | Injector: Christoph Hertzberg, MD (Germany) |
14:00 – 14:30 | Pretarsal or orbital injections? The art of eyelid watching and prevention and management of side effects post injection Bettina Wabbels, MD (Germany) |
14:00 – 14:30 | Neuronal hypotheses and data on the mechanisms of action of botulinum toxin injections in psychiatric disorders Tillmann H. C. Krüeger, MD (Germany) |
14:00 – 15:30 | Katharine Alter, MD (USA) Heakyung Kim, MD (USA) Serdar Koçer, MD (Switzerland) Michael Munin, MD (USA) Sophie Cho, MD (USA) Barbara Karp, MD (USA) Atul Patel, MD (USA) Panagiotis Kassavetis, MD, PhD (USA) Yeva Fernandez, MD (USA) |
|||||||
| 14:20 – 14:40 | The effects of botulinum neurotoxins in the intestine in a mouse model of foodborne botulism Ornella Rossetto, PhD (Italy) |
14:25 – 14:50 | Dose, duration, onset of action, and patient satisfaction: Are all botulinum toxins created equal? Patricia Ogilvie, MD (Germany) |
14:30 – 15:00 | Botulinum toxin and multimodal treatments for functional recovery in post-stroke spasticity Areerat Suputtitada, MD (Thailand) |
14:20 – 14:40 | Sialorrhea Anna Rita Bentivoglio, MD, PhD (Italy) |
14:30 – 15:00 | Challenges in the treatment of Meige syndrome Marie-Helene Marion, MD (UK) |
14:30 – 15:00 | Botulinum toxin as a treatment for depression – current data situation Marc Axel Wollmer, MD (Germany) |
|||||||||||
| 14:40 – 15:00 | Elongated iBoNT: A new botulinum neurotoxin construct for treatment of chronic pain Charlotte Leese, PhD (UK) |
14:50 – 15:05 | Reversing muscle weakness caused by botulinum neurotoxin in the glabellar region: A proof-of-concept study Steve Yoelin, MD (USA) |
14:40 – 15:00 | Tremor Shivam Mittal, MD (United Arab Emirates) |
|||||||||||||||||
| 15:00 – 15:20 | Botulinum neurotoxin type A hijacks a heterotrimeric plasma membrane complex to intoxicate neurons Merja Joensuu, PhD (Australia) |
15:05 – 15:30 | Neuromodulators from around the world: What’s here and what’s to come Nowell Solish, MD (Canada) |
15:00 – 15:30 | Botulinum toxin treatment trends in patients with spasticity: A population-based study from France Djamel Bensmail, MD, PhD (France) |
15:00 – 15:20 | BoNT in the management of bladder dysfunction in patients post stroke or with Parkinson's disease Dudley Robinson, MBBS, MD, FRCOG (UK) |
15:00 – 15:15 | Treatment of blepharospasm in progressive supranuclear palsy with botulinumtoxin: A retrospective comparative study Lejla Paracka, MD (Germany) |
15:00 – 15:30 | OnabotulinumtoxinA in resistant depression: A new paradigm comparing two facial injection sites (OnaDep study) Danièle Ranoux, MD (France) |
|||||||||||
| 15:20 – 15:30 | Botulinum neurotoxin type DC (BoNT/DC) blocks melanocyte melanogenesis Birgitte Sondergaard, PhD (USA) |
15:20 – 15:30 | Panel Discussion |
15:15 – 15:30 | Botulinum neurotoxin treatment combined with motor learning exercises for Pisa syndrome in Parkinson’s disease – a case study Anna Castagna, MD (Italy) |
|||||||||||||||||
| 15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
15:30 – 16:15 | Break Poster and Exhibit Hall Open Educational Theatre |
|||||||
| Time | Basic Science Track Room I |
Time | Clinical Track 2B Estrel C |
Time | Clinical Track 3B Convention Hall I A/B |
Time | Clinical Track 4B Estrel A/B |
Time | Clinical Track 5B Room V |
Time | Clinical Track 6B Room IV |
Time | Clinical Track 7B Paris | |||||||||
| 16:15 – 17:45 | Toxin Detection and Countermeasures Chair: Suzy Kalb, PhD (USA) Co-Chair: Patrick McNutt, PhD (USA) |
16:15 – 17:45 | Hot Topics Chair: Alberto Albanese, MD (Italy) |
16:15 – 17:45 | Injection Demonstration Workshop: Patients With Parkinson’s Disease, Task-Specific/Focal Limb Dystonias Moderator: Robert Chen, MD (Canada) |
16:15 – 17:45 | Injection Demonstration Workshop: Adult Spasticity Moderator: Chris Boulias, MD, PhD (Canada) |
16:15 – 17:45 | Use of BoNTs in Urology Chair: Dudley Robinson, MBBS, MD, FRCOG (UK) |
16:15 – 17:45 | Cervical Dystonia Issues and Insights Chair: Ryuji Kaji, MD (Japan) |
16:15 – 17:45 | Ultrasound Workshop: Head & Neck and Upper/Lower Limb Chair: Katharine Alter, MD (USA) |
|||||||||
| 16:15 – 16.35 | Laboratory confirmation during a large cross-border outbreak of iatrogenic botulism in Europe in 2023 Martin Dorner, PhD (Germany) |
16:15 – 16:45 | Challenges in BoNT adherence: Impact of goal-setting, financial barriers, clinic logistics Atul Patel, MD (USA) |
16:15 – 17:45 | Injectors: David Weise, MD (Germany) |
16:15 – 17:45 | Injectors: Tobias Bäumer, MD (Germany) Jörg Wissel, MD, FRCP (Germany) |
16:15 – 16.45 | Mechanism of action in the bladder (motor & sensory) Christopher Chermansky, MD (USA) |
16:15 – 16.45 | Botulinum toxin for the management of cervical dystonia: Why do patients discontinue treatment and how can we do better? Jaroslaw Slawek, MD (Poland) |
16:15 – 17:45 | Katharine Alter, MD (USA) Heakyung Kim, MD (USA) Serdar Koçer, MD (Switzerland) Steffen Berweck, MD (Germany) Sebastian Schroeder, MD (Germany) Michael Munin, MD (USA) Panagiotis Kassavetis, MD, PhD (USA) Sophie Cho, MD (USA) Yeva Fernandez, MD (USA) |
|||||||||
| 16:35 – 16:55 | Detection of active BoNTs by EndoPep-MS: Is it feasible in standard microbiology laboratories? Ilenia Drigo, PhD (Italy) |
16:45 – 17:45 | Prevention and management of side effects after injection of the neck and throat Lucy Hicklin, MD (UK) |
16:45 – 17:15 | Management of overactive bladder: The role of botulinum toxin Dudley Robinson, MBBS, MD, FRCOG (UK) |
16:45 – 17:15 | Treating pain in cervical dystonia with BoNT Hyder (Buz) Jinnah, MD, PhD (USA) |
|||||||||||||||
| 16:55 – 17:15 | X-BAT: Research on and generation of a decavalent equine antitoxin counteracting deliberate botulinum neurotoxin attacks Emmanuel Lemichez, PhD (France) |
|||||||||||||||||||||
| 17:15 – 17:30 | Botulinum toxin type A antinociceptive activity in spinal cord and trigeminal sensory nociceptive nuclei involves central trans-synaptic transport Dalia Nemanić, MPharm (Croatia) |
17:15 – 17:45 | Clinical update on the use of BoNT in urology Christopher Chermansky, MD (USA) |
17:15 – 17:45 | Observations from a clinical investigator on treating cervical dystonia with a new BoNT formulation Peter McAllister, MD (USA) |
|||||||||||||||||
| 17:30 – 17:45 | Facial neuromuscular junctions and selected brainstem nuclei are the targets of tetanus neurotoxin in cephalic tetanus Federico Fabris, PhD (Italy) |
|||||||||||||||||||||
| Saturday, 20 January 2024 | |
|---|---|
| 7:30 – 12:00 | Information |
| 7:30 – 9:00 | Breakfast Poster and Exhibit Hall Open |
| 9:00 – 12:00 | Convention Hall I - A/B Plenary Session Chair: Katharine Alter, MD (USA) |
| 9:00 – 9:10 | Welcome Back Katharine Alter, MD (USA) |
| 9:10 – 10:00 | Questions about BoNT you were afraid to ask Moderator: David Simpson, MD (USA) Giampietro Schiavo, PhD, FMedSci, FRSB (UK) Nowell Solish, MD (Canada) Katharine Alter, MD (USA) Francisco Cardoso, MD (Brazil) Ornella Rossetto, PhD (Italy) |
| 10:00 – 10:10 | Best Clinical Abstract |
| 10:10 – 10:20 | Best Basic Science Abstract |
| 10:20 – 10:50 | Advances in urology: Indications, outcomes and new modes of BoNT delivery Dudley Robinson, MBBS, MD, FRCOG (UK) |
| 10:50 – 11:20 | Long-acting botulinum toxin Peter McAllister, MD (USA) |
| 11:20 – 11:50 | BoNT sero- and sub-type–specific neuronal selectivity Andreas Rummel, PhD (Germany) |
| 11:50 – 12:00 | Closing Remarks Katharine Alter, MD (USA) |